PD-1 inhibitor + rituximab + methotrexate + orelabrutinib

This combination regimen, abbreviated as PD-1i+RMO, is a multi-agent therapeutic approach being investigated by The First Affiliated Hospital with Nanjing Medical University. It is specifically designed for patients with newly diagnosed primary central nervous system lymphoma (ND-PCNSL) and secondary central nervous system lymphoma (SCNSL). The regimen integrates four distinct therapeutic modalities: a PD-1 inhibitor (a monoclonal antibody that blocks the PD-1/PD-L1 pathway to restore T-cell mediated anti-tumor immunity), rituximab (a chimeric monoclonal antibody targeting the CD20 antigen on B-lymphocytes), methotrexate (a high-dose antimetabolite chemotherapy that penetrates the blood-brain barrier), and orelabrutinib (a highly selective, second-generation Bruton's tyrosine kinase inhibitor). By combining immune checkpoint inhibition with targeted B-cell depletion and cytotoxic chemotherapy, the regimen aims to improve complete response rates and progression-free survival in aggressive CNS-localized B-cell malignancies.

Other names

PD-1 inhibitor combined with rituximab, methotrexate, and orelabrutinib